Question 1

What is the size of the Asia Pacific cancer supportive care drugs industry?

Accepted Answer

Asia Pacific industry is set to witness 2.3% CAGR from 2023-2032 and reach USD 6.1 billion by 2032 driven by the rising incidence of cancer due to population growth, aging, changing lifestyles, and environmental factors.

Question 2

Which are the top firms operating in the cancer supportive care drugs market?

Accepted Answer

Some of the top companies in the industry are Amgen, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Heron Therapeutics, Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd., Helsinn Healthcare SA, Teva Pharmaceuticals Industries Ltd., and Fagron Group.

Question 3

Why is the demand for G-CSFs gaining traction in the cancer supportive care drugs industry?

Accepted Answer

The G-CSFs (granulocyte-colony stimulating factors) segment accounted for 22.8% share in the cancer-supportive care drugs market owing to its extensive usage to avoid neutropenia.

Question 4

How big is the cancer supportive care drugs market?

Accepted Answer

Global market for cancer supportive care drugs was worth USD 14.4 billion in 2022 and is estimated to expand at 1.9% CAGR from 2023-2032 attributed to the growing progress in cancer treatments, such aschemotherapy, radiation therapy, targeted therapy, and immunotherapy.

Cancer Supportive Care Drugs Market Share

Cancer Supportive Care Drugs Market Share

Premium Report Details

Industries

Information

Link

Global Headquarters